Extensive serum biomarker analysis in patients with ST segment elevation myocardial infarction (STEMI)

•21 cytokines differed considerably between STEMI patients and healthy controls.•BNDF, PDGF-AA and MMP-9 were clinically validated increase in AMI patients.•These three cytokines showed 80%, 90%, and 100% in specificity with the sensitivity ranging between 70% and 80%.•These three cytokines represen...

Full description

Saved in:
Bibliographic Details
Published in:Cytokine (Philadelphia, Pa.) Pa.), 2015-12, Vol.76 (2), p.356-362
Main Authors: Zhang, Yi, Lin, Peiyi, Jiang, Huilin, Xu, Jieling, Luo, Shuhong, Mo, Junrong, Li, Yunmei, Chen, Xiaohui
Format: Article
Language:English
Subjects:
Acute myocardial infarction (AMI)
Antibody array
Biomarkers - blood
Cross-Sectional Studies
Cytokines - blood
Enzyme-Linked Immunosorbent Assay
Female
Humans
Male
Middle Aged
Myocardial Infarction - blood
Myocardial Infarction - physiopathology
Serum cytokine
STEMI
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•21 cytokines differed considerably between STEMI patients and healthy controls.•BNDF, PDGF-AA and MMP-9 were clinically validated increase in AMI patients.•These three cytokines showed 80%, 90%, and 100% in specificity with the sensitivity ranging between 70% and 80%.•These three cytokines represented up-regulation in AMI samples, and may hold promise for the assessment of AMI. ST segment elevation myocardial infarction (STEMI) is one of the leading causes of morbidity and mortality and some characteristics of STEMI are poorly understood. The aim of the present study is to detect protein expression profiles in the serum of STEMI patients, and to identify biomarkers for this disease. Cytokine profiles of serum from STEMI patients and healthy controls were analyzed with a semi-quantitative human antibody array for 174 proteins, and the results showed blood serum concentrations of 21 cytokines differed considerably between STEMI patients and healthy subjects. In the next phase, a sandwich ELISA kit individually validated eight biomarker results from 21 of the microarray experiments. Clinical validation demonstrated a significant increase of BNDF, PDGF-AA and MMP-9 in patients with AMI. Meanwhile, BNDF, PDGF-AA and MMP-9 distinguished AMI patients from healthy controls with a mean area under the receiver operating characteristic (ROC) curves of 0.870, 0.885, and 0.81, respectively, with diagnostic cut-off points of 0.688ng/mL, 297.86ng/mL and 690.066ng/mL. Our study indicated that these three cytokines were up-regulated in STEMI samples, and may hold promise for the assessment of STEMI.
ISSN:1043-4666
1096-0023
DOI:10.1016/j.cyto.2015.06.015